Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

NCT06781034 | Recruiting

• 1 other identifier: Local/2024/TP-02
• Study Type: observational
• Target: 128
• Locations: 1 country
• Sites: 1

Brief Summary

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

Conditions

Cerebral Hemorrhage; Acute Lobar Haematoma

Keywords

Cerebral haemorrhage; MRI

Outcome Measures

Primary Outcomes (3)

• Presence of spot sign on gadolinium MRI

  Presence of spot sign on gadolinium MRI (Yes/No)

  baseline

• Morphologic description of gadolinium MRI spot sign

  morphological (shape, location within the hematoma) description of spot signs on brain MRI

  baseline

• Quantitative description of gadolinium MRI spot sign

  Quantitative (number and categorial) description of spot signs on brain MRI

  baseline

Secondary Outcomes (2)

• association of spot sign with hematoma expansion on follow-up CT

  Baseline

• Association with the underlaying pathology

  Baseline

Study Arms (1)

patients with acute lobar and deep haematoma

None, pure observational study

Other: None, pure observational study

Interventions

None, pure observational study OTHER

None, pure observational study

patients with acute lobar and deep haematoma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with acute cerebral hematoma from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy; who underwent a follow-up cerebral CT scan in the event of worsening or for follow-up.

You may qualify if:

• Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
• Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

You may not qualify if:

• Patient refusing to participate

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de Nîmes

Nîmes, Gard, 30029, France

RECRUITING

MeSH Terms

Conditions

Cerebral Hemorrhage

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Anissa MEGZARI

  Centre Hospitalier Universitaire de Nīmes

  STUDY DIRECTOR

Central Study Contacts

Teodora PARVU

CONTACT

04.66.68.32.61; teodora.parvu@chu-nimes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2025
• First Posted: January 17, 2025
• Study Start: February 3, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: July 1, 2026

Record last verified: 2026-06

Locations

FR (1)